Featuring perspectives from Prof Nicolas Girard, Dr Jonathan Goldman, Dr Pasi A Jänne, Dr Suresh S Ramalingam, Dr Joshua K Sabari and Dr Helena Yu, moderated by Dr Yu, including the following topics:

• Introduction (0:00)
• Evolving First-Line Treatment for Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) — Dr Yu (1:47)
• EGFR-Targeted Approaches for Relapsed EGFR-Mutant NSCLC; Strategies to Facilitate Delivery of Recently Approved Agents — Dr Sabari (23:48)
• Potential Utility of TROP2-Targeted Therapy in the Management of EGFR-Mutant NSCLC — Dr Ramalingam (45:16)
• Contemporary Care for Patients with Nonmetastatic EGFR-Mutant NSCLC — Dr Goldman (1:03:56)
• Current and Future Management of EGFR Exon 20 Mutation-Positive NSCLC — Prof Girard (1:24:40)
• Emerging Role of HER3-Targeted Therapy in the Management of EGFR-Mutant NSCLC — Dr Jänne (1:43:46)

CME information and select publications

Featuring perspectives from Dr Geoffrey Y Ku and Dr Zev Wainberg, including the following topics:

• Introduction: ASCO Preview (0:00)
• HER2-Positive Gastroesophageal Cancers (19:03)
• Immunotherapy in HER2-Negative Advanced Gastroesophageal Cancers (36:11)
• Immunotherapy in Microsatellite Instability-High Gastroesophageal Cancers (44:04)
• CLDN18.2-Positive Advanced Gastroesophageal Cancers (51:30)

CME information and select publications

Featuring perspectives from Prof Meletios-Athanasios (Thanos) C Dimopoulos and Dr Robert Z Orlowski, including the following topics:

• Introduction: ASCO 2025 Preview (0:00)
• Anti-CD38 Antibodies (10:12)
• Belantamab Mafodotin (29:45)
• CAR T-Cell Therapy (40:57)
• Bispecific Antibodies (47:33)
• Other Novel Agents (56:46)

CME information and select publications